Drug Profile
Transdermal estradiol gel - BHR Pharma
Alternative Names: BHR-200Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator BHR Pharma
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 11 Sep 2018 No recent reports on development identified - Phase-II for Prostate cancer in USA (Topical)
- 01 Mar 2017 BHR Pharma terminates a phase II trial in Prostate cancer in USA (NCT02349386) due to inability to recruit patients
- 01 Jul 2015 Phase-II clinical trials in Prostate cancer in USA (Topical) (NCT02349386)